CAT

715.77

+1.65%↑

GE

291.23

-2.39%↓

RTX

193.41

-2.23%↓

GEV.US

898.23

-0.32%↓

BA

196.58

-1.71%↓

CAT

715.77

+1.65%↑

GE

291.23

-2.39%↓

RTX

193.41

-2.23%↓

GEV.US

898.23

-0.32%↓

BA

196.58

-1.71%↓

CAT

715.77

+1.65%↑

GE

291.23

-2.39%↓

RTX

193.41

-2.23%↓

GEV.US

898.23

-0.32%↓

BA

196.58

-1.71%↓

CAT

715.77

+1.65%↑

GE

291.23

-2.39%↓

RTX

193.41

-2.23%↓

GEV.US

898.23

-0.32%↓

BA

196.58

-1.71%↓

CAT

715.77

+1.65%↑

GE

291.23

-2.39%↓

RTX

193.41

-2.23%↓

GEV.US

898.23

-0.32%↓

BA

196.58

-1.71%↓

Search

Kadant Inc

Open

BrancheIndustrie

312.23 -0.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

306.66

Max

314.78

Schlüsselkennzahlen

By Trading Economics

Einkommen

-3.7M

24M

Verkäufe

15M

286M

KGV

Branchendurchschnitt

34.957

61.065

Dividendenrendite

0.45

Gewinnspanne

8.394

Angestellte

3,900

EBITDA

-15M

54M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+15.22% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.45%

2.23%

Nächstes Ergebnis

28. Apr. 2026

Nächste Dividendenausschüttung

13. Mai 2026

Nächstes Ex-Dividendendatum

15. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-373M

3.6B

Vorheriger Eröffnungskurs

312.84

Vorheriger Schlusskurs

312.23

Nachrichtenstimmung

By Acuity

43%

57%

159 / 406 Ranking in Industrials

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Kadant Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. März 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. März 2026, 22:55 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. März 2026, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. März 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. März 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. März 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. März 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. März 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. März 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. März 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. März 2026, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. März 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. März 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. März 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. März 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. März 2026, 21:10 UTC

Wichtige Nachrichtenereignisse

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. März 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk
Ergebnisse
Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Kadant Inc Prognose

Kursziel

By TipRanks

15.22% Vorteil

12-Monats-Prognose

Durchschnitt 341.5 USD  15.22%

Hoch 380 USD

Tief 303 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Kadant Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

293.2 / 303.41Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

159 / 406 Ranking in Industrie

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Kadant Inc

Kadant Inc. supplies technologies and engineered systems worldwide. It operates in three segments: Flow Control, Industrial Processing, and Material Handling. The Flow Control segment develops, manufactures, and markets fluid-handling systems and equipment, such as rotary joints, syphons, turbulator bars, expansion joints, and engineered steam and condensate systems; and doctoring, cleaning, and filtration systems and related consumables consisting of doctor systems and holders, doctor blades, cleaning shower and fabric-conditioning systems, forming systems and wear surfaces, and water-filtration systems. The Industrial Processing segment develops, manufactures, and markets ring and rotary debarkers, stranders, chippers, engineered knife systems, industrial automation and control, recycling and approach flow systems, and virgin pulping process equipment for use in the packaging, tissue, wood products, and alternative fuel industries. The Material Handling segment offers conveying and vibratory equipment, and baling products; and manufactures and sells biodegradable absorbent granules for carriers in agricultural, home lawn and garden, professional lawn, turf, and ornamental applications, as well as for oil and grease absorption. The company markets and sells its products, services, and systems through direct sales, independent sales agents, and distributors. The company was formerly known as Thermo Fibertek, Inc. and changed its name to Kadant Inc. in July 2001. Kadant Inc. was incorporated in 1991 and is headquartered in Westford, Massachusetts.
help-icon Live chat